Melanotan I

FDA-approved product existsMelanocortin Receptor AgonistSkin & hair
6.2

Worth trying, BioHarmony verdict

BioHarmony score 6.2 out of 10

Melanotan I is most defensible for photoprotection in EPP and planned UV exposure, with Langendonk 2015 reporting 69.4 vs 40.8 hours of pain-free sun exposure in the US trial. The wellness case is narrower than the prescription afamelanotide evidence.

Read full report

What is Melanotan I?

Melanotan I (Afamelanotide) is a synthetic MC1R-selective alpha-MSH analog with prescription-grade evidence for erythropoietic protoporphyria, where Langendonk reported 69.4 versus 40.8 hours of pain-free sun exposure in the US Phase III arm. Afamelanotide works by increasing eumelanin through MC1R, which explains why the upside is strongest for photoprotection and pigment-related use cases. Melanotan I earns a worth-trying score because regulated SCENESSE has meaningful human evidence and the intrinsic afamelanotide safety profile is manageable with dermatology monitoring.

From the BioHarmony report, reviewed Sep 8, 2026.

Saved on this device only.

How it is thought to work

MC1R activation increases eumelanin and UV tolerance

Safety watch-outs

  • New or rapidly changing mole, oral pigmentation, or bleeding lesion
  • Severe headache, confusion, vision change, chest pain, or neurologic symptoms
  • Priapism, severe abdominal pain, dark urine, or muscle pain after dosing

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

Approved labelSCENESSE prescribing information for erythropoietic protoporphyria
PopulationAdults with a history of phototoxic reactions from erythropoietic protoporphyria
DoseOne 16 mg implant
RouteSubcutaneous implant inserted by a trained healthcare professional
FrequencyEvery 2 months
DurationThree implants were administered in the pivotal trials; the approved label controls clinical use
PreparationSterile 16 mg implant supplied for professional subcutaneous insertion; not a vial and not reconstituted.
Source: Dosage and Administration section 2; Dosage Forms and Strengths section 3

Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (2)

Attributed viewpoints, separate from primary research.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalFDA-approved product exists
CompoundingAfamelanotide has an approved implant product; other products represented as Melanotan I are not thereby FDA approved

The registry alias Melanotan I maps to afamelanotide. FDA-approved afamelanotide is marketed as Scenesse to increase pain-free light exposure in adults with erythropoietic protoporphyria, not as a general tanning product.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.